An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Sponsor: Repertoire Immune Medicines

Sponsor score: 0

ClinicalTrials ID:NCT07293754

This trial assesses RPTR-1-201's safety and antitumor activity in adults with advanced solid tumors. It includes dose escalation and expansion phases, testing RPTR-1-201 alone and with a PD-1/PD-L1 monoclonal antibody. Eligible participants are adults with advanced solid tumors. Interventions involve RPTR-1-201 and a PD-1/PD-L1 monoclonal antibody.

Patient Parameters

Program Overview

This is an early phase trial designed to evaluate the safety, tolerability, and preliminary antitumor activity of RPTR-1-201 in adults with advanced solid tumors. The trial includes dose escalation and dose expansion parts and will evaluate RPTR-1-201 as monotherapy and in combination with an anti-PD-1 monoclonal antibody.

Eligibility Criteria

Exclusion Criteria

  • History of another malignancy within 3 years before the first dose of trial intervention, with the exception of malignancies considered cured and not expected to require active therapy (for example, certain skin cancers or in situ malignancies) per protocol.
  • Known active leptomeningeal disease or uncontrolled central nervous system metastases.
  • Active, clinically significant, autoimmune diseases requiring systemic immunosuppressive therapy.
  • Prior allogenic organ transplantation
  • Clinically significant uncontrolled medical or psychiatric condition, that in the opinion of the investigator, would increase risk or interfere with trial participation.
  • Other protocol-defined inclusion and exclusion criteria apply

Locations

FACILITYZIPCITYSTATE
START Midwest49546Grand RapidsMichigan

Get This Program In Your Inbox

You can sign up and apply your patients for this program.